Practical study on the impact of injection conditions in gradient elution mode for the analysis of therapeutic proteins when using very short columns.
Loading capacity
injection volume
ion exchange chromatography
monoclonal antibodies
proteins
ultra-short columns
Journal
Journal of chromatography. A
ISSN: 1873-3778
Titre abrégé: J Chromatogr A
Pays: Netherlands
ID NLM: 9318488
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
25
07
2023
revised:
31
08
2023
accepted:
01
09
2023
pubmed:
18
9
2023
medline:
18
9
2023
entrez:
17
9
2023
Statut:
ppublish
Résumé
The impact of injected sample volume on apparent efficiency has been studied for very short columns in a systematic way. For large molecules such as therapeutic proteins, it was found that relatively large volumes can be injected onto ultra-short RPLC and IEX columns (i.e. L < 50 mm) without significantly affecting the quality of the separation. This favourable behavior is due to the on-off elution mechanism of large molecules and to the fact that therapeutic protein samples are formulated in aqueous-based media, which is the weakest solvent in RPLC and IEX. Therefore, their peak is strongly focused at the column inlet even when large volume is injected, and pre-column peak dispersion is compensated. However, ultra-short HILIC columns do not seem to be favorable, as they require for very low injection volume to avoid detrimental peak splitting and breakthrough effects. Such peak distortion is related to the inherent solvent mismatch between sample diluent (aqueous) and mobile phase strength (highly organic in HILIC). When studying mass load, the ranking of the elution modes was the same, and the largest relative mass could be injected onto IEX columns (as large as 10% sample to sorbent mass), without affecting the separation quality.
Identifiants
pubmed: 37717303
pii: S0021-9673(23)00584-8
doi: 10.1016/j.chroma.2023.464359
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
464359Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ACQUITY, UPLC, Empower and BEH are trademarks of Waters Technologies Corporation. MabThera is a trademark of F. Hoffmann-La Roche AG. Kineret is a trademark of Swedish Orphan Biovitrum AB.